Impedimed Limited (AU:IPD) has released an update.
ImpediMed Limited announces that the U.S. National Accreditation Program for Breast Centers (NAPBC) has updated its breast care standards to recommend lymphoedema prevention programs, including the use of bioimpedance spectroscopy (BIS), a technology where ImpediMed leads with its FDA-cleared SOZO Digital Health Platform. This endorsement coincides with Breast Cancer Awareness month and underscores the significance of ImpediMed’s technology in enhancing survivorship care for breast cancer patients. The updated standards are expected to influence clinicians and healthcare facilities across the United States.
For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.
